Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 5/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.32 |
| ▸ | PPARD | Q03181 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | TRPV3 | Q8NET8 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4868378 | 0.88 | ALOX5AP (0.32) | ALOX5APMDM2MCHR1 | |
| SCHEMBL14304770 | 0.86 | ALOX5AP (0.40) | ALOX5APMDM2 | |
| SCHEMBL4877910 | 0.86 | ALOX5AP (0.36) | ALOX5APDHODH | |
| SCHEMBL4873951 | 0.85 | GRIN2B (0.38) | — | |
| SCHEMBL4871839 | 0.85 | ALOX5AP (0.40) | ALOX5APMDM2CSNK1D | |
| SCHEMBL4876033 | 0.84 | KCNH2 (0.40) | DHODH | |
| SCHEMBL4868351 | 0.84 | AKR1A1 (0.35) | DHODH | |
| SCHEMBL14269763 | 0.82 | KCNH2 (0.36) | — | |
| SCHEMBL4867702 | 0.82 | FFAR1 (0.33) | — | |
| SCHEMBL4868456 | 0.82 | ALDH1A1 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
| US-20080051384-A1 | ANTIVIRAL AGENTS | GENELABS TECHNOLOGIES, INC. | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080051384-A1 | ANTIVIRAL AGENTS | EIF2AK2, MAVS, ZC3HAV1 | ALOX5AP 3943/4885MDM2 2661/4885MCHR1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.